Hives (Chronic Urticaria) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 120 pages | ID: HC322BB4AC13EN
VPAResearch

Abstracts

2020 Hives (Chronic Urticaria) PIPELINE HIGHLIGHTS
Hives (Chronic Urticaria) is one of the widely researched conditions during 2020 with 25 companies actively focusing on realizing pipeline’s potential. Development of Hives (Chronic Urticaria) medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Hives (Chronic Urticaria) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Hives (Chronic Urticaria).

Good progress is anticipated during 2020 and 2021 with Hives (Chronic Urticaria) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Hives (Chronic Urticaria) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Hives (Chronic Urticaria) DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Hives (Chronic Urticaria) pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Hives (Chronic Urticaria) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Hives (Chronic Urticaria) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Hives (Chronic Urticaria) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Hives (Chronic Urticaria) DRUG PROFILES
Hives (Chronic Urticaria) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Hives (Chronic Urticaria) COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Hives (Chronic Urticaria) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Hives (Chronic Urticaria). Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 25 Hives (Chronic Urticaria) companies including company overview, key snapshot, contact information, and their strategies on accelerating Hives (Chronic Urticaria) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Allakos Inc, BiosanaPharma BV, Celldex Therapeutics Inc, Celltrion Inc, Eli Lilly and Co, ELORAC Inc, Faes Farma SA, Genentech Inc, GI Innovation Co Ltd, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Gossamer Bio Inc, Kolmar Korea Holdings Co Ltd, Kyowa Kirin Co Ltd, Mycenax Biotech Inc, Novartis AG, Oneness Biotech Co Ltd, RAPT Therapeutics Inc, Regeneron Pharmaceuticals Inc, Roche, Sorrento Therapeutics, STERO Biotechs Ltd, Synermore Biologics Co Ltd, United Biomedical Inc, United BioPharma Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Hives (Chronic Urticaria)
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO HIVES (CHRONIC URTICARIA)

1.1 Hives (Chronic Urticaria)- Disease overview
1.2 Hives (Chronic Urticaria)- Market Size
1.3 Hives (Chronic Urticaria)- Companies Involved

2. HIVES (CHRONIC URTICARIA) PIPELINE SNAPSHOT- 2020

2.1 Hives (Chronic Urticaria) Pipeline by Phase
2.2 Hives (Chronic Urticaria) Pipeline by Mechanism of Action
2.3 Hives (Chronic Urticaria) Pipeline by Route of Administration
2.4 Hives (Chronic Urticaria) Pipeline- New Molecular Entities
2.5 Hives (Chronic Urticaria) Pipeline- Orphan Drug Designation/ Special Designation

3. HIVES (CHRONIC URTICARIA) DRUG PROFILES

3.1 Current Status
3.2 Hives (Chronic Urticaria) Drug Snapshot
3.3 Hives (Chronic Urticaria) Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Allakos Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.2 BiosanaPharma BV Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.3 Celldex Therapeutics Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.4 Celltrion Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.5 Eli Lilly and Co Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.6 ELORAC Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.7 Faes Farma SA Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.8 Genentech Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.9 GI Innovation Co Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.10 GlaxoSmithKline Plc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.11 Glenmark Pharmaceuticals Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.12 Gossamer Bio Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.13 Kolmar Korea Holdings Co Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.14 Kyowa Kirin Co Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.15 Mycenax Biotech Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.16 Novartis AG Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.17 Oneness Biotech Co Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.18 RAPT Therapeutics Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.19 Regeneron Pharmaceuticals Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.20 Roche Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.21 Sorrento Therapeutics Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.22 STERO Biotechs Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.23 Synermore Biologics Co Ltd Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.24 United Biomedical Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials
4.25 United BioPharma Inc Hives (Chronic Urticaria) Pipeline Insights and Clinical Trials

5. HIVES (CHRONIC URTICARIA) MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information